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We have studied the expression of the C3b receptor 
(CR1) on erythrocytes of 55 patients with Hansen's 
disease. We developed a radioimmunoassay utilizing a 
monoclonal antibody that recognized an epitope differ-
ent from the C3b binding site, which therefore enabled 
us to measure total number of CR1 regardless of recep-
tor occupancy. We observed that patients in the lepro-
matous pole of the disease had a mean of 310 CR1/ 
erythrocyte, whereas the ones in the tuberculoid pole 
showed a mean of 577 CR1/erythrocyte; 77 normal con-
trols had a mean of 512 CR1/erythrocyte. The number 
of C3b receptors on the cells of lepromatous patients 
was significantly decreased (p < .001) when compared 
to the normal population or tuberculoid patients. The 
presence of receptors for the C3b fragment of comple-
ment (CR1) on the surface of human erythrocytes en-
ables these cells to participate in a number of immune 
functions including the clearance of circulating immune 
complexes. These findings could bear importance in the 
ability of the host to clear immune complexes from the 
circulation in patients with lepromatous leprosy. 
The receptor for the C3b fragment of t he third component 
of the human complement system (CR1) was first reported 
more than 30 years ago as the immune adherence receptor. 
This molecule was demonstrated by t he binding of particles 
coated with complement fragments to primate erythrocytes and 
nonprimate platelets [1 ,2]. Subsequent ly it has been shown 
that CR1 is a lso present on the surface of a variety of human 
blood and tissue ce ll s such as polymorphonuclear (PMN), 
monocytes, and B lymphocytes [3], subsets of T lymphocytes 
[4), macrophages a nd glomerular podocytes [5], and Langer-
hans cells [6]. 
CR1 has been isolated and characterized as a 250,000 Mr 
glycoprotein [7], expressing a number of regulatory properties 
in t he functi on of the complement system [8]. It accelerates 
t he decay of C3 cleaving enzymes of both the alternative [9] 
and classical pathways [10], and acts as a cofactor for Factor I 
in the degradation of t he c/ cha in of the C4b and C3b fragments, 
converting t hem to t heir inactive form s, C4c- C4d and C3bi 
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BB: Borderline leprosy 
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DGVB: veronal-buffered saline (0.075 M NaCI) containing 2.5% 
dextrose and 0.5% gelat in 
EDTA: 0.02 M ethylenediamine tetraacetate 
LL: lepromatous leprosy 
RA: rheumatoid arthritis 
SLE: systemic lupus erythematosus 
TT: tuberculoid leprosy 
[ll] . Therefore this receptor contributes to prevent t he dam-
aging effect of complement deposition on host cells. 
An important biological function of CR1 is its participation 
in the clearance of immune complexes. It has been reported 
t hat circulating immune complexes (CIC) carrying C3b bind to 
the receptor on erythrocyte membranes [12,13] and are carried 
by these cells to the liver where they are processed by loca l 
macrophages [14] . This processing of CIC apparently can be 
prevented by complement depletion, under such condition t hey 
deposit in tissues liable to suffer immune complex-mediated 
injury [15] . Clinical relevance for these concepts has been 
inferred from the observation that certain autoimmune dis-
eases, such as systemic lupus erythematosus (SLE) and rheu-
matoid arthritis (RA), have a marked reduction in t he expres-
sion of CR1 on their erythrocytes [16- 18]. 
In this study we provide additional evidence for the linkage 
between CR1 levels and diseases which feature an altered 
immune response. We examined patients with various forms of 
leprosy, motivated by the spectrum that spans from leproma-
tous leprosy, known to have high levels of ere to the tubercu-
loid pole, featuring low or absent levels of immune complexes 
[19,20] . These studies have shown that the patients with the 
lepromatous form of the disease show a selective reduction in 
erythrocyte-associated CRl. 
MATERIALS AND METHODS 
Patients 
Fifty-five patients diagnosed as having Hansen's disease were seen 
and followed in the San Diego Hansen's Disease Clinic. They were 
classified accordi ng to clinical and histopathological features [21] as 
lepromatous, borderline and tuberculoid leprosy. Only 3 patients were 
untreated at the time of the study. The patient population groups are 
summarized in Table I. The control population consisted of 77 healthy 
race matched volunteers ranging in age from 19- 71 years. 
Purified CRI and Anti-CRI Monoclonal Antibodies 
CR1 was purified to homogeneity from human erythrocytes accord-
ing to published methods [9,22]. Murine monoclonal antibodies were 
produced by using a modification [23] of the method of Kohler and 
Milstein [24]. Mice were immunized by 2 i.p. injections with 10 /J.g of 
purified CRL Spleen cells were fused with the murine myeloma line 
P3 x 63.AG8.653 at a ratio of 6:1. The antibodies produced by clone 
543 were tested using purified CR1 in an enzyme- linked immunoabsor-
bent assay (ELISA) . The ascites t1uid was passed through a protein A-
agarose column (EY, San Mateo, California) equilibrated with 0.1 M 
phosphate buffer pH 8.0, and the bound lgG was eluted with 0.1 M 
acetic acid. Fab fragments were obtained by digesting the IgG with 2% 
w/w pepsin (Sigma, St. Louis, Missouri) for 18 hat 37°C, pH 4, in the 
presence of 0.02 M Cys-HCl (Sigma, St. Louis, Missouri); 0.025 M 
iodoacetamide was then added and the fragments were purified by high-
performance liquid chromatography (HPLC) (Waters, Milford, Mas-
sachusetts) gel filtration on a 7.5 X 600 mm TSK-250 column (BioRad, 
Richmond, Californ ia). 
C3b Dimers 
C3 was purified according to Tack and Prahl [25 ]. C3b dimers were 
generated by incubating C3 with 0.6% wjw trypsin for 6 min at 37°C, 
and subsequent addition of an excess of soybean trypsin inhibitor 
(Sigma) as described [26]. Separation of C3b monomers and dimers 
was achieved by gel filtration on Sephadex G-150 equilibrated with 1 
M NaCl 50 mM Na acetate. C3b eluted from the column in two peaks; 
one consisted of a high molecular weight protein of 360,000 daltons 
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representing C3b dimers, wh ile the second peak. contained C3b mono-
mers of 180,000 daltons, as judged by sodium dodecyl sulfate-polyacryl-
amide gel e lectrophoresis (SDS-PAGE) . 
Radiolabeling of A nti-CR I Fab and C3b Dimers with 125/ 
The Fab fragments of a nti-CR1 a nd C3b dimers were labeled with 
J25 J (New England Nuclea r, Boston, Massachusetts) using iodogen-
coated tubes (Pierce, Rockford, Illinois) , according to the manufactur-
er's instructions. Free and bound 1251 were separated by centrifugation 
th rough tubes of Bio-gel P6 (BioRad) (27]. 
Quantitation of CR J 
A radiobindipg assay was developed to measure CR1 on erythrocyte 
surfaces using 12''1-Fab fragments to the monoclonal anti-CR1 lgG I 
(MoAB 543). Ten 11 ! of venous blood we re drawn in 0.02 M ethylene-
diamine tetraacetate (EDTA, Fisher Scient ific, Fairlawn, New Jersey), 
filtered over glass wool and washed 3X in veronal-buffered saline 
(VBS), removing a ny remaining huffy coat afte r each wash. The eryth -
rocytes were t hen resuspended at a concentration of 2.5 X 10"/ml in 
VBS (0.075 M NaCI) containing 2.5% dextrose (Malli nkrodt, Paris, 
Kentucky) , and 0.5% gelatin (J . T. Baker, Phillipsburg, New Jersey) 
(DGVB) . Fifty J.LI of eryth rocytes were incubated on ice with 50 11! of 
increasing dilutions of 1251-Fab anti-CR1 in DGVB ranging from 6.5 to 
0.4 11gjml. After 60 min, t he mixtures were layered onto 200 J.Ll of 
dibutylphthalate (Eastman Kodak, Rochester, New York) in 400 11! 
polypropylene microfuge tubes (BioRad). Following centrifugation for 
1 min at 8000 g in a microfuge B (Beckman , Palo Alto, Cal ifo rnia), the 
tubes were sectioned and the sections containing pellets and superna-
tants were a nalyzed for bound and free 1251-Fab. Nonspecific binding 
was determined by incubating erythrocyte samples with a 200-fold 
excess of unlabeled anti-CR1 lgG for 60 min before adding the 1251-
Fab. The number of CR1 molecules per ce ll was calculated by binding 
isotherms a nd Scatchard analysis of the binding data corrected for 
nonspecific binding. 
TABLE I. Clinical distribution according to patient 's origin 
----~M~e~x~ic~o~ __________ P_hi~lip~p_in_e_s ______ V_ie~t_na~m ______ O __ th_e_r ____ _ 
LL: 18 
BL: 1 
88: 1 
8T: 1 
TT:O 
LL: 3 LL: 1 LL:3 
BL:3 BL: 1 BL:O 
88: 4 88: 2 88: 0 
BT: 2 BT: 1 BT: 2 
TT:2 TT:8 TT:2 
Abbreviations: LL = lepromatous, BL = borderline lepromatous, BB 
= borderline , BT = borderline tuberculoid , TT = tuberculoid. 
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RESULTS 
T he mean number of CR1 molecules per erythrocyte for each 
group of patients is shown in Fig 1. Patients with lepromatous 
leprosy had a mean number of CR1 per erythrocyte of 310 ± 
33 SEM, significantly different (p = < 0.001), from the number 
of CR1 measured in an age- and sex-matched group of healthy 
individuals (512 ± 36 SEM). The values obtained in the pa-
tients with tuberculoid leprosy (577 ± 76 SEM) did not differ 
significantly from the control population (p = > 0.3). Patients 
with borderline leprosy had a lower number CR1 (443 ± 41 
SEM); however this difference was not statistically sign ificant 
(p = 0.1). CR1levels on erythrocyte surface of normal individ-
uals as well as patients tested at various times throughout 6 
months showed no significant variation. 
A table of our patient population shows a distinct pattern of 
clinical expression associated with the ethnic background of 
the patient. Of our 55 patients, 18 were of Mexican origin and 
had lepromatous leprosy. Nine of 14 Filipinos had borderline 
leprosy (3 BL, 4 BB, 2 BT) and 8 of 13 Vietnamese had 
tuberculoid leprosy. The remaining 7 patients studied were of 
other origins. 
To determine if t he monoclonal antibody was bound to an 
epitope of t he CR1 different from the C3b binding site, fresh 
erythrocytes were incubated with a 10-fold saturating dose of 
unlabeled C3b dimers, and the CR1 expression was measured 
with anti-CR1 Fab as detailed in Materials and Methods. As 
shown in Fig 2, t he saturation of erythrocytes with C3b dimers 
did not interfere with the measurement of CR1 molecules 
utilizing 1251-Fab. The inverse, that is, the saturation of the 
cell s with the antireceptor antibody did not affect the saturable 
binding of 1251-C3b dimers (not shown). These experiments 
showed that the monoclonal anti-CR1 used measures total 
number of CR1, regardless of receptor occupancy. 
At t he t ime of the study only 3 patients were without treat-
ment; when assayed after treatment the number of CR1 per 
erythrocyte did not change, alt hough, due to t he small size of 
this population, no conclusions can be drawn. However, since 
both t he lepromatous and t he tuberculoid patients received 
similar ant ibacterial t reatment (dapsone, rifampin), and pa-
tients receiving thalidomide did not differ in CR1 expression 
from other lepromatous patients, it is unlikely that therapy had 
FIG 1. Number of CRl (C3b recep-
tors) on eryth rocytes of normal volun-
tee rs, lepromatous (LL), tuberculoid 
(TT) , and borderline (B) patients. Open 
circles represent patients with leproma-
:j tous leprosy that had erythema nodosum leprosum at t he time of the study. Analy-
sis of the data by I.-test and nonpara-
metric tests showed a significant differ-
ence (p < .001) between LL and TT 
patients as well as between LL patients 
and normals. Bars represent means ± 
SEM for each group. 
TT 
n-12 
l-577 
p<.J 
60s 
(!) 
(!) 
.... 
--...... 
"0 
.4 
3 .2 
0 
Ill 
TAUSK ET AL 
A. B. 
2 4 6 8 2 4 
125 1-Fab Bound (ng) 
any effect in t he diminished expression of CR1 in lepromatous 
individuals. 
DISCUSSION 
T he receptor on huma n erythrocytes for C3b, t he activation 
p roduct of t he t hird component of complement, has been shown 
to play an important role in t he clearance of CIC. The relative 
high concentration of erythrocytes in the blood stream assigns 
t hem t he major role in t he binding of circulating C3b bearing 
pa rt icles [28], in spi te of having less CR1 on t heir surface t ha n 
leukocytes . Indeed, it has recently been shown t hat white cells 
do not contribu te s ignificant ly to t he binding of CIC [15]. A 
number of reports show a reduct ion of CR1 molecules on the 
surface of erythrocytes of patients wi t h systemic lupus as well 
as RA, suggesting t hat t his alteration could resul t in an im-
pairment in t he cleara nce of CIC. Ge netic studies performed in 
normal subjects and SLE patients have shown t hat the CR1 
levels a re inheri ted in a codomina n t fashion [18]. These resul ts 
raise t he poss ibili ty t hat t he decrease in levels of CRl on 
erythrocyte surfaces serve as a marker that may predispose 
individuals to ce rtain diseases. Contra ry to thi s notion , Iida , 
Morn aghi a nd N ussenzweig [1 7] reported in SLE patients an 
increase in CR1 express ion on erythrocytes when t heir disease 
evolved favo rably, implying t he acquired nature of t he changes 
in recepto r density. 
In t he presen t st udy we investigated t he levels of erythrocyte 
CR1 in a group of norma l individuals and in patients diagnosed 
as having H a nse n's disease. We found that t he average number 
of CRl (5 12 ± 25 SEM), as well as t he wide scatte r of values, 
in our norma l population is in agreemen t wi t h t hat reported by 
Wil son et al [18]. Al t hough t he over-all distribution of the 
number of recepto rs according to high, inte rmediate, and low, 
is also in agreement wi t h publi shed data [18], our results fa iled 
to show clea r ev idence of cluste ring of t hese groups. We ob-
served t hat patients wi t h lepromatous leprosy have a dec reased 
number of CRl molecules on t heir erythrocyte surface (310 ± 
33 SEM), whereas tuberculoid patients do not differ from t he 
normal population (577 ± 76 SEM) . The levels of CR1 in 
patients wi t h borderline leprosy were 443 ± 41 SEM, not 
significant ly di ffe rent from t he healt hy age- a nd sex-matched 
cont rol group (p = < 0.1). Patients assayed 2 or more ti mes 
during 6 mont hs did not show substant ial variation in t he 
exp ression of erythrocyte-assoc iated CRl. This period is prob-
ably insufficient considerin g t he extended course of t his pa rt ic-
ular disease. Long-term studies will provide evidence as to 
whether t he levels of CRl in borderline patients will co rrelate 
wit h t he possible shift in cl inical a nd histopathological features 
towa rds one of t he poles in t he disease p rocess. 
Studies to measure t he p resence of CIC in t he blood of t he 
sa me group of patients showed t hat t hose individuals diagnosed 
as having t he lepromatous form of Ha nsen's di sease have high 
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FIG 2. Effect of cell-bound C3b cli-
mers on erythrocyte CR1 quantitation. 
Scatchard analysis of binding of anti-
CR1 1251-labeled Fab to cells previously 
incubated wi th buffer (A) or C3b dimers 
(B) . 
levels of immune complexes which contain IgG and IgM im-
munoglobulins. In contrast, patients wit h tuberculoid leprosy 
did not (unpublished observat ion) . These findings may suggest 
t hat t he reduct ion in t he number of CR1 per erythrocyte 
observed in patients with lepromatous leprosy is due to receptor 
occupancy. The observation t hat the monoclonal used to meas-
ure CR1 recognizes an epitope in t he receptor distinct from t he 
binding s ite (Fig 2) excludes t his possibility. 
These studies could support the notion that the number of 
CR1 on erythrocytes is a predictive ma rker for suscept ibility to 
acquire a given clinical expression of a disease, or in t he case 
of Ha nsen 's disease determine the clinical form of t he disease. 
The decreased levels of CRl on erythrocytes of patien ts wit h 
lepromatous leprosy could result in an impairment to correctly 
process CIC. 
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